• Introduction:
    Dr. Gabrielle Rocque is an Associate Professor of Medicine in the Divisions of Hematology & Oncology and Gerontology, Geriatrics, & Palliative Care at the University of Alabama at Birmingham (UAB). She completed her undergraduate degree, medical doctorate, Internal Medicine residency, and fellowship in Hematology & Oncology at the University of Wisconsin- Madison. She also completed a Masters of Science in Public Health from UAB.

    Clinical interests:

    She currently practices as a medical oncologist, specializing in the care of women with breast cancer.


    Dr. Rocque’s research interests include improving the quality of healthcare delivery for cancer patients with an emphasis on shared decision-making, payment reform, and provision of supportive care services to patients. She served as Medical Director a successful 2012 Center for Medicare and Medicaid Innovation Award, which focused on improving health and healthcare costs by implementing a lay navigator workforce to support cancer patients across from diagnosis through survivorship and end-of-life. She also received an American Cancer Society Mentored Research Scholar Grant to develop treatment plans aimed to enhance shared decision making for patients with metastatic breast cancer and a National Institute of Nursing Research R01 to evaluate the implementation of home symptom monitoring. She is active within UAB’s payment reform initiatives, and serves as the co-Director of UAB’s Oncology Care Model Steering Committee. Dr. Rocque has a strong interest in the interface between community oncology practices and academia. She is a former chair of the American Society of Clinical Oncology (ASCO) Measures Task Force and the ASCO Quality of Care Committee.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 Barriers to COVID-19 vaccine uptake among resource-limited adults diagnosed with chronic illnessFrontiers in Public Health.  11. 2023
    2023 Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancerBreast Cancer Research and Treatment.  197:673-681. 2023
    2023 Oncologist-Reported Barriers and Facilitators to Enrolling Patients in Optimization Trials That Test Less Intense Cancer TreatmentJco Oncology Practice.  19:e263-e273. 2023
    2023 Tenets for Implementing Electronic Patient-Reported Outcomes for Remote Symptom Monitoring During Cancer Treatment.JCO Clinical Cancer Informatics.  7:e2200187. 2023
    2023 Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort.Jco Oncology Practice.  OP2200464. 2023
    2023 Cost-Effectiveness of Pharmacologic Treatment Options for Women with Endocrine-Refractory or Triple-Negative Metastatic Breast CancerJournal of Clinical Oncology.  41:32-42. 2023
    2022 Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials 2022
    2022 Adaptation of Remote Symptom Monitoring Using Electronic Patient-Reported Outcomes for Implementation in Real-World SettingsJco Oncology Practice.  18:E1943-E1952. 2022
    2022 Evaluating the implementation and impact of navigator-supported remote symptom monitoring and management: a protocol for a hybrid type 2 clinical trialBMC Health Services Research.  22. 2022
    2022 Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocatesBMC Cancer.  22. 2022
    2022 The impact of race and ethnicity in breast cancer—disparities and implications for precision oncologyBMC Medicine.  20. 2022
    2022 Associations between geography, decision-making style, and interest in cancer clinical trial participationCancer.  128:3977-3984. 2022
    2022 Ineligible, Unaware, or Uninterested? Associations between Underrepresented Patient Populations and Retention in the Pathway to Cancer Clinical Trial EnrollmentJco Oncology Practice.  18:E1854-E1865. 2022
    2022 Vaccine Hesitancy versus Vaccine Behavior in Patients with Chronic IllnessJournal of Health Care for the Poor and Underserved.  33:2007-2031. 2022
    2022 Determinants of telemedicine adoption among financially distressed patients with cancer during the COVID-19 pandemic: insights from a nationwide studySupportive Care in Cancer.  30:7665-7678. 2022
    2022 Harvest for Health, a Randomized Controlled Trial Testing a Home-Based, Vegetable Gardening Intervention Among Older Cancer Survivors Across Alabama: An Analysis of Accrual and Modifications Made in Intervention Delivery and Assessment During COVID-19Journal of the Academy of Nutrition and Dietetics.  122:1629-1643. 2022
    2022 Improving outcomes demands patient-centred interventions and equitable deliveryNature Reviews Clinical Oncology.  19:569-570. 2022
    2022 Growing the Next Generation of Oncology Researchers and OncologistsJco Oncology Practice.  18:559-561. 2022
    2022 Health insurance and financial hardship in cancer survivors during the COVID-19 pandemicPLoS One.  17. 2022
    2022 Impact of lay navigation on utilization and Medicare spending for cancer survivors in the “Deep South”Journal of Cancer Survivorship.  16:705-713. 2022
    2022 Primary care and preventable hospitalizations among Medicare beneficiaries with non-metastatic breast cancerJournal of Cancer Survivorship.  16:853-864. 2022
    2022 Building Sustainable Practice Transformation Through Payment Reform InitiativesJco Oncology Practice.  18:E731-E739. 2022
    2022 Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States 2022
    2022 A lay navigator-led, early palliative care intervention for African American and rural family caregivers of individuals with advanced cancer (Project Cornerstone): Results of a pilot randomized trialCancer.  128:1321-1330. 2022
    2022 Survival in the Real World: A National Analysis of Patients Treated for Early-Stage Breast CancerJco Oncology Practice.  18:E235-E249. 2022
    2022 Exclusion criteria of breast cancer clinical trial protocols: a descriptive analysisBreast Cancer Research and Treatment.  191:471-475. 2022
    2022 Learning from Real-world Implementation of Daily Home-Based Symptom Monitoring in Patients with CancerJAMA Network Open.  5. 2022
    2022 Patient-reported discrimination among limited-resourced cancer survivors: a brief reportJournal of Psychosocial Oncology2022
    2022 The Relationship Between Prior Cancer Diagnosis and All-Cause Dementia Progression Among US AdultsJournal of Alzheimer's Disease.  88:521-535. 2022
    2021 An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerBreast Cancer Research.  23. 2021
    2021 Association between cancer treatment and progression of all-cause dementiaAlzheimer's and Dementia.  17:e054164. 2021
    2021 Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancerBreast Cancer Research and Treatment.  190:531-540. 2021
    2021 Examining the association among fear of COVID-19, psychological distress, and delays in cancer careCancer Medicine.  10:8854-8865. 2021
    2021 Pathway to Precision Patient-Reported OutcomesJournal of Clinical Oncology.  39:3770-3772. 2021
    2021 Secret Sauce—How Diverse Practices Succeed in Centers for Medicare & Medicaid Services Oncology Care ModelJco Oncology Practice.  17:734-743. 2021
    2021 Satisfaction and Regret With Decision Making in Older Women With Breast Cancer 2021
    2021 The missing voice in multidisciplinary tumor boardsJournal of Geriatric Oncology.  12:1157-1158. 2021
    2021 Exclusion Criteria of Breast Cancer Clinical Trial Protocols: A Descriptive Analysis 2021
    2021 Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer. 2021
    2021 Implementation of the Institute of Medicine Treatment Plan in Oncology PracticeAmerican Journal of Medical Quality.  36:311-319. 2021
    2021 Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast CancerClinical Breast Cancer.  21:292-301. 2021
    2021 Patient perspectives on chemotherapy de-escalation in breast cancerCancer Medicine.  10:3288-3298. 2021
    2021 The Impact of Depression on Health Care Utilization in Patients with CancerJournal of Palliative Medicine.  24:755-759. 2021
    2021 Quantifying treatment preferences and their association with financial toxicity in women with breast cancerCancer.  127:449-457. 2021
    2021 Treatment Decision Making and Financial Toxicity in Women With Metastatic Breast CancerClinical Breast Cancer.  21:37-46. 2021
    2021 “It's important to me”: A qualitative analysis on shared decision-making and patient preferences in older adults with early-stage breast cancer 2021
    2020 Oncologic services through project access and other safety net care coordination programsJco Oncology Practice.  16:E1489-E1498. 2020
    2020 Health care-related time costs in patients with metastatic breast cancerCancer Medicine.  9:8423-8431. 2020
    2020 POLARIS: A prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancerFuture Oncology.  16:2475-2485. 2020
    2020 Should we be talking about guidelines with patients? A qualitative analysis in metastatic breast cancerBreast Cancer Research and Treatment.  184:115-121. 2020
    2020 Trust but Verify: Exploring the Role of Treatment-Related Information and Patient-Physician Trust in Shared Decision Making Among Patients with Metastatic Breast CancerJournal of Cancer Education.  35:885-892. 2020
    2020 Heightened Tamoxifen Activation Masquerading as a Venlafaxine-Associated Adverse Event After Rotation From DuloxetineJournal of Pain and Symptom Management.  60:e104-e106. 2020
    2020 Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology cliniciansCancer.  126:3534-3541. 2020
    2020 "i'd Want to Know, because a Year's Not a Long Time to Prepare for a Death": Role of Prognostic Information in Shared Decision Making among Women with Metastatic Breast CancerJournal of Palliative Medicine.  23:937-943. 2020
    2020 Urban versus rural residence and outcomes in older patients with breast cancerCancer Epidemiology, Biomarkers and Prevention.  29:1313-1320. 2020
    2020 Health Insurance Literacy and Financial Hardship in Women Living with Metastatic Breast CancerJco Oncology Practice.  16:E529-E537. 2020
    2020 Prior treatment time affects survival outcomes in metastatic breast cancerJCO Clinical Cancer Informatics.  500-513. 2020
    2020 Clinical Cancer Advances 2020: Annual report on progress against cancer from the American Society of Clinical oncologyJournal of Clinical Oncology.  38:1081-1101. 2020
    2020 How Do We Align Health Services Research and Quality Improvement?American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting.  40:1-10. 2020
    2020 Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE)Journal of Geriatric Oncology.  11:270-273. 2020
    2020 Patient-reported outcomes in the Translational Breast Cancer Research ConsortiumCancer.  126:922-930. 2020
    2020 Study protocol for a multisite randomised controlled trial of a rehabilitation intervention to reduce participation restrictions among female breast cancer survivorsBMJ Open.  10. 2020
    2020 Why Aren’t we choosing wisely?Jco Oncology Practice.  16:443-445. 2020
    2019 The project ENABLE Cornerstone randomized pilot trial: Protocol for lay navigator-led early palliative care for African-American and rural advanced cancer family caregiversContemporary Clinical Trials Communications.  16. 2019
    2019 Healthy lifestyle discussions between healthcare providers and older cancer survivors: Data from 12 cancer centers in the Southeastern United StatesCancer Medicine.  8:7123-7132. 2019
    2019 Hypofractionated radiation in older women with breast cancer 2019
    2019 Patient Navigation in Cancer: The Business Case to Support Clinical NeedsJco Oncology Practice.  15:585-590. 2019
    2019 What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists 2019
    2019 An examination of the relationship between patient satisfaction with healthcare and quality of life in a geriatric population with cancer in the Southeastern United StatesJournal of Geriatric Oncology.  10:787-791. 2019
    2019 Lay navigation across the cancer continuum for older cancer survivors: Equally beneficial for Black and White survivors?Journal of Geriatric Oncology.  10:779-786. 2019
    2019 Impact of travel time on health care costs and resource use by phase of care for older patients with cancerJournal of Clinical Oncology.  37:1935-1945. 2019
    2019 Disparities in Hospice Utilization for Older Cancer Patients Living in the Deep SouthJournal of Pain and Symptom Management.  58:86-91. 2019
    2019 Evaluating the impact of treatment care planning on quality measuresJco Oncology Practice.  15:E271-E276. 2019
    2019 How family caregivers of persons with advanced cancer assist with upstream healthcare decision-making: A qualitative studyPLoS One.  14. 2019
    2019 Unmet social support needs among older adults with cancerCancer.  125:473-481. 2019
    2019 Bridging the data-free zone: Decision making for older adults with cancerJournal of Clinical Oncology.  37:3469-3472. 2019
    2019 Engaging multidisciplinary stakeholders to drive shared decision-making in oncologyJournal of Palliative Care.  34:29-31. 2019
    2019 Guideline discordance and patient cost responsibility in medicarebeneficiaries with metastatic breast cancerJournal of the National Comprehensive Cancer Network : JNCCN.  17:1221-1228. 2019
    2019 Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast Cancer 2019
    2019 Quality Improvement at the Health System Level: Measurement, Risk Stratification, Disparity Populations, and Governance.American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting.  39:388-398. 2019
    2019 Visualization of sequential treatments in metastatic breast cancerJCO Clinical Cancer Informatics.  1-8. 2019
    2018 Factors Associated with Family Caregivers' Confidence in Future Surrogate Decision Making for Persons with CancerJournal of Palliative Medicine.  21:1705-1712. 2018
    2018 Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasisCancer.  124:4231-4240. 2018
    2018 Choosing Wisely at the End of Life: Use of Shorter Courses of Palliative Radiation Therapy for Bone Metastasis 2018
    2018 First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional studyAnnals of Oncology.  29:viii112-viii113. 2018
    2018 Impact of nonconcordance with NCCN guidelines on resource utilization, cost, and mortality in de novo metastatic breast cancerJournal of the National Comprehensive Cancer Network : JNCCN.  16:1084-1091. 2018
    2018 Hospice care, cancer-directed therapy, and Medicare expenditures among older patients dying with malignant brain tumorsNeuro-Oncology.  20:986-993. 2018
    2018 Adapting an Early Palliative Care Intervention to Family Caregivers of Persons With Advanced Cancer in the Rural Deep South: A Qualitative Formative EvaluationJournal of Pain and Symptom Management.  55:1519-1530. 2018
    2018 Possible underestimation of the provision of palliative careJAMA Oncology.  4:884-885. 2018
    2018 Where are the opportunities for reducing health care spending within alternative payment models?Jco Oncology Practice.  14:e375-e383. 2018
    2018 Lay patient navigators’ perspectives of barriers, facilitators and training needs in initiating advance care planning conversations with older patients with cancerJournal of Palliative Care.  33:70-78. 2018
    2018 Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary educationTranslational Behavioral Medicine.  8:175-182. 2018
    2018 Participation and interest in support services among family caregivers of older adults with cancer 2018
    2018 Most impactful factors on the health-related quality of life of a geriatric population with cancerCancer.  124:596-605. 2018
    2018 Radiation therapy utilization in Medicare beneficiaries with early-stage breast cancerCancer.  124:475-481. 2018
    2018 What is the role of symptom management and patient-reported outcomes in adherence to aromatase inhibitors?Journal of Clinical Oncology.  36:308-309. 2018
    2018 Healthcare utilization, Medicare spending, and sources of patient distress identified during implementation of a lay navigation program for older patients with breast cancerBreast Cancer Research and Treatment.  167:215-223. 2018
    2017 Choosing wisely in oncology: Are we ready for value-based care?Jco Oncology Practice.  13:e935-e943. 2017
    2017 Hospital-based end-of-life care and costs for older patients with malignant brain tumorsJAMA Oncology.  3:1581-1582. 2017
    2017 The self-care practices of family caregivers of persons with poor prognosis cancer: differences by varying levels of caregiver well-being and preparednessSupportive Care in Cancer.  25:2437-2444. 2017
    2017 Feasibility of a Telehealth Educational Program on Self-Management of Pain and Fatigue in Adult Cancer PatientsJournal of Pain and Symptom Management.  53:1071-1078. 2017
    2017 Resource use and medicare costs during lay navigation for geriatric patients with cancerJAMA Oncology.  3:817-825. 2017
    2017 Implementation and Impact of Patient Lay Navigator-Led Advance Care Planning ConversationsJournal of Pain and Symptom Management.  53:682-692. 2017
    2017 Establishing a core set of performance measures to improve value in cancer care: ASCO consensus conference recommendation reportJco Oncology Practice.  13:135-140. 2017
    2017 Choosing wisely: Opportunities for improving value in cancer care delivery?Jco Oncology Practice.  13:e11-e21. 2017
    2016 Patient-centered support in the survivorship care transition: Outcomes from the Patient-Owned Survivorship Care Plan InterventionCancer.  122:3232-3242. 2016
    2016 Adherence to the Choosing Wisely Campaign Recommendations for Radiation Treatment Duration in Breast Cancer: Analysis of Medicare Data at 12 Centers in the Southeastern United States. 2016
    2016 Intensity Modulated Radiation Therapy in Breast Cancer: Analysis of Medicare Data at 12 Institutions. 2016
    2016 Treatment summaries and follow-up care instructions for cancer survivors: Improving survivor self-efficacy and health care utilization 2016
    2016 The patient care connect program: Transforming health care through lay navigationJco Oncology Practice.  12:e633-e640. 2016
    2016 Integrating palliative care into the oncology clinic: A joint management approachPalliative Medicine.  30:510-512. 2016
    2016 Guiding lay navigation in geriatric patients with cancer using a distress assessment toolJournal of the National Comprehensive Cancer Network : JNCCN.  14:407-414. 2016
    2015 A Quantitative Study of Triggered Palliative Care Consultation for Hospitalized Patients with Advanced Cancer the results of Cohorts 1 and 2 were presented at the 2014 Annual Assembly of the American Academy of Hospice and Palliative Medicine (AAHPM) and the Hospice and Palliative Nurses Association (HPNA).Journal of Pain and Symptom Management.  50:462-469. 2015
    2014 Guiding lay navigation using the distress thermometer.Journal of Clinical Oncology.  32:195. 2014
    2014 Update on adjuvant chemotherapy for early breast cancerBreast Cancer: Basic and Clinical Research.  8:125-133. 2014
    2014 Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindlesScience Translational Medicine.  6. 2014
    2014 Development and evaluation of a survey to assess survivor knowledge change after survivorship care plans: WiSDOM-B (Wisconsin survey of cancer DiagnOsis and management in breast cancer)Journal of Cancer Education.  29:270-277. 2014
    2013 Reply to A. Azad et alJco Oncology Practice.  9. 2013
    2013 Palliative care reduces morbidity and mortality in cancerNature Reviews Clinical Oncology.  10:80-89. 2013
    2013 Inpatient hospitalization of oncology patients: Are we missing an opportunity for end-of-life care?Jco Oncology Practice.  9:51-54. 2013
    2012 Adjuvant therapy for HER2+ breast cancer: Practice, perception, and toxicityBreast Cancer Research and Treatment.  131:713-721. 2012
    2011 An Unusual Presentation of Liver Failure in a Patient with Primary Gastrointestinal Hodgkin's Lymphoma 2011
    2011 MiRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapyBlood.  118:1034-1040. 2011
    2011 The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformationBlood.  117:3391-3401. 2011

    Research Overview

  • Shared decision making, value, Metastatic breast cancer, Supportive care, Payment reform
  • Principal Investigator On

  • Enhancing Shared Decision Making in Metastatic Breast Cancer  awarded by American Cancer Society, Inc.
  • Evaluating Adoption and Outcomes of Early Stage Breast Cancer Clinical Trials Results in Underrepresented and Unrepresented Populations  awarded by Johnson (Robert Wood) Foundation
  • Evaluating Shared Decision Making in Cancer  awarded by CANCERCARE
  • Evaluating the Implementation and Impact of Navigator-delivered ePRO Home Symptom Monitoring and Management  awarded by National Institute of Nursing Research/NIH/DHHS
  • Impact Of Guideline Concordant Treatment On Cost And Health Care Utilization In Early Stage Breast Cancer Patients  awarded by UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER (SAN ANTONIO)
  • Komen Leadership Grant SAC170001  awarded by Johns Hopkins University
  • Memorandum of Understanding with BCBSAL - Evaluating the Implementation and Impact of Navigator-delivered ePRO Home Symptom Monitoring and Management  awarded by BLUE CROSS AND BLUE SHIELD OF ALABAMA
  • Navigating Under Resourced Patients and their Engagement with Technology  awarded by American Cancer Society, Inc.
  • Outliers - Extreme Long-term Survivors with Metastatic Breast Cancer  awarded by University of Wisconsin-Madison
  • Private Grant  awarded by PACKHEALTH
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Safety Net Program Survey: Launched 07/05/2017  awarded by PATIENT ADVOCATE FOUNDATION
  • TBCRC 029_Clinical and Biological Characterization of Male Breast Cancer  awarded by Johns Hopkins University
  • TBCRC-AURORA US: A Prospective Biospecimen Repository in Metastic Breast Cancer  awarded by Johns Hopkins University
  • Variation in Cancer Centers’ End-of-Life Quality: Role of Norms  awarded by Dartmouth College
  • Investigator On

  • A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases  awarded by Dana-Farber Cancer Institute
  • A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), In Patients with Her2-Positive Metastatic Breast Cancer who have Progressed on Prior Trastuzumab and Pertuzumab: The "AVIATOR” Study  awarded by Johns Hopkins University
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • CITY Health II - The Center for the Study of Community Health  awarded by National Center for Chronic Disease Prevention & Health Promo./CDC/DHHS
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Enabling A Paradigm Shift: A Preference-Tolerant RCT of Personalized vs Annual Screening of Breast Cancer (WISDOM)  awarded by QUANTUM LEAP HEALTH CARE
  • Harvest for Health in Older Cancer Survivors  awarded by National Cancer Institute/NIH/DHHS
  • Health Care Innovation Challenge  awarded by Centers for Medicare and Medicaid Services/DHHS
  • Lay Coach-led Early Palliative Care for Underserved Advanced Cancer Caregivers  awarded by National Cancer Institute/NIH/DHHS
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by Novartis Pharma AG
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by ARQULE
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by ONCOTHYREON, INC.
  • Private Grant  awarded by PHARMACYCLICS, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by EMD SERONO
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by TESARO, INC.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS
  • Private Grant  awarded by TESARO, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SERMONIX PHARMACEUTICALS INC
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by DAIICHI SANKYO, INC.
  • Private Grant  awarded by LILLY USA, LLC
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by CYTOMX THERAPEUTICS
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by CELCUITY
  • Private Grant  awarded by CELCUITY
  • Private Grant  awarded by GREENWICH LIFESCIENCES, INC.
  • Private Grant  awarded by BRIACELL THERAPEUTICS CORP.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by CELCUITY
  • Quantifying the Burden of Breast Cancer Decision Making in Older Women  awarded by American Society of Clinical Oncology
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University
  • TBCRC 037 UAB 1644:A Trial of Endocrine Response In Women with Invasive Lobular Breast Cancer.  awarded by University of Pittsburgh The
  • TBCRC 048 UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes  awarded by Johns Hopkins University
  • TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer  awarded by Johns Hopkins University
  • TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer  awarded by Johns Hopkins University
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University
  • UAB 1326: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer  awarded by Washington University
  • UAB 1643- A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer  awarded by Columbia University
  • UAB 17127-A Phase 1b Trial of Fulvestrant, Palbociclib (CDK4/6 inhibitor) and Erdafitinib (JNJ-42756493, Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2–/FGFR-Amplified Metastatic Breast Cancer (MBC)  awarded by VANDERBILT UNIVERSITY
  • UAB 1761: A Randomized, Placebo-Controlled, Double-Blind, Phase II trial of Nanoparticle Albumin-Bound Paclilaxel (Nab-Paclilaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple Negative Breast Cancer.  awarded by University of Chicago ^
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)  awarded by VANDERBILT UNIVERSITY
  • Utilizing Multiomic Advanced Diagnostics to Identify Palbociclib Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer  awarded by THE SIDE-OUT FOUNDATION
  • XUAB 2167 - A Phase II Circulating Tumor DNA Enriched, Gnomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer (PERSEVERE): HCRN BRE18-334  awarded by HOOSIER CANCER RESEARCH NETWORK
  • XUAB2107-A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)  awarded by HOOSIER CANCER RESEARCH NETWORK
  • XUAB2147-Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of DNA Damage Response (DDR) Inhibitor (Olaparib) Followed by Adjuvant Combination of Durvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases  awarded by HOOSIER CANCER RESEARCH NETWORK
  • [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Women with Newly Diagnosed Metastatic Breast Cancer (R20-146)  awarded by ECOG-ACRIN CANCER RESEARCH GROUP
  • Education And Training

  • University of Wisconsin Hospital & Clinics, Residency
  • University of Wisconsin Hospital & Clinics, Postdoctoral Fellowship
  • Doctor of Medicine, University of Wisconsin System : Madison 2007
  • Full Name

  • Gabrielle Rocque